VANCOUVER, Nov. 20, 2019 /CNW/ – THC BioMed Intl Ltd. (CSE:THC) (“THC BioMed” or the “Company“) is excited to announce that it has submitted its cannabis beverage, THC KISS, for approval under the Cannabis Act as a new product by Health Canada. After the approval, it will be available for sale.

About THC KISS

“THC KISS is a brand new cannabis beverage that is not available in either the grey or legal cannabis markets. THC Kiss was developed by THC BioMed using proprietary extraction methods invented by THC BioMed. We remain a true cannabis company that is fully integrated with passion and understanding of cannabis. Our operational procedures have proven successful and we have demonstrated that we have the ability to scale at low cost while producing the finest quality cannabis at a very reasonable cost to the end consumer,” said John Miller, President & CEO of THC BioMed.

Health Canada requires a 60-day notice period before any new cannabis product can be made available for sale.

“We are excited about the future and look forward to capturing market share and scaling up accordingly. We expect our gross margins to increase and predict growth in sales this coming year,” commented John Miller.

About the company

THC BioMed is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. THC BioMed is Canada’s largest supplier of legal Cannabis Genetics. The Company is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC BioMed is well-positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available and to know more about THC KISS.  www.thcbiomed.com

SOURCE THC BioMed

The post “THC Kiss” submitted to Health Canada for approval appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.

Source: CLN